Diuretics in the treatment of patients who present congestive heart failure and hypertension

Journal of Human Hypertension

Volumn 16, Issue , 2002, Pages S104-S113

  Reyes, A J ^a  

^a Institute of Cardiovascular Theory Montevideo   (Uruguay)

Author keywords

Congestive heart failure; Diuretics; Hypertension; Hypokalaemia; Hyponatraemia; Spironolactone

Indexed keywords

AMILORIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BENZOTHIADIAZINE DERIVATIVE; BUMETANIDE; CANRENOATE POTASSIUM; CARBOHYDRATE; CHLORTALIDONE; CICLETANINE; CLOPAMIDE; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ETACRYNIC ACID; FUROSEMIDE; INDAPAMIDE; LOOP DIURETIC AGENT; LOSARTAN; MAGNESIUM; METOLAZONE; PIRETANIDE; POTASSIUM; POTASSIUM SPARING DIURETIC AGENT; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TIENILIC ACID; TORASEMIDE; TRIAMTERENE; UNINDEXED DRUG; XIPAMIDE;

BODY FLUID; BODY WEIGHT; BREATHING MUSCLE; CLINICAL TRIAL; COMORBIDITY; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; DISORDERS OF ACID BASE BALANCE; DISORDERS OF CARBOHYDRATE METABOLISM; DIURETIC THERAPY; DOSE RESPONSE; DRUG CHOICE; DRUG EFFECT; DRUG EFFICACY; DRUG MONITORING; DRUG POTENTIATION; DRUG SAFETY; DRUG USE; DYSPNEA; EXERCISE; FATIGUE; HEART OUTPUT; HEART SIZE; HOSPITALIZATION; HUMAN; HYPERCALCEMIA; HYPERKALEMIA; HYPERTENSION; HYPERURICEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; KALIURESIS; KIDNEY FUNCTION; LIFE EXPECTANCY; LUNG CONGESTION; LUNG VENTILATION; MAGNESIUM DEFICIENCY; MAINTENANCE THERAPY; MEDICAL DECISION MAKING; MYOPATHY; NEUROENDOCRINE SYSTEM; RESPIRATORY FUNCTION; SYSTEMIC CIRCULATION; SYSTOLE;

DIURETICS; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; SPIRONOLACTONE;

EID: 0036233598     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001354     Document Type: Article

References (100)

1. Reyes AJ. Pathophysiological basis of the use of diuretics in congestive heart failure. Prog Pharmacol Clin Pharmacol 1995; 10/3: 75-89.
2. Coodley EL, Nandi PS, Chiotellis P. Evaluation of a new diuretic, diapamide, in congestive heart failure. J Clin Pharmacol 1979; 19: 127-136.
3. Dixon DW, Barwold-Gohlke C, Gunnar RM. Comparative efficacy and safety of bumetamide and furosemide in long-term treatment of edema due to congestive heart failure. J Clin Pharmacol 1981; 21: 680-687.
4. Kupper AJF et al. Cross-over comparison of the fixed combination of hydrochlorothiazide and triamterene and the free combination of furosemide and triamterene in the maintenance treatment of congestive heart failure. Eur J Clin Pharmacol 1986; 30: 341-343.
5. Achhammer I. Long term efficacy and tolerance of tora-semide in congestive heart failure. Prog Pharmacol Clin Pharmacol 1990; 8/1: 127-136.
6. Rutishauser W, Rhomberg F, Sack P. Uber die Veran-derungen der Kreislaufzeiten bei der Behandlung der hamodynamischen Herzinsuffizienz mit Diuretica und Herzglycosiden. Helv Med Acta 1960; 27: 729-734.
7. Nishijima H et al. Acute and chronic hemodynamic effects of the basic therapeutic regimen for congestive heart failure. Diuretics, low salt diet and bed rest. Jpn Heart J 1984; 25: 571-585.
8. Haerer W et al. Acute and chronic effects of diuretic monotherapy with piretanide in congestive heart failure-a placebo-controlled trial. Cardiovasc Drugs Ther 1990; 4: 515-522.
9. Sverzellati E et al. Lung water is a critical determinant of functional capacity in congestive heart failure. J Cardiac Fail 1998; 4 (Suppl 1): 15 (abstract).
10. Reyes AJ. The Stanley H. Taylor Memorial Lecture: diuretics in heart failure. Understanding the mechanism of the clinical improvement. In: Reyes AJ, Maranhao MFC (eds). Cardiovascular Pharmacotherapy. Proceedings of the 9th International Congress on Cardiovascular Pharmacotherapy. Monduzzi: Bologna, 2000, pp 91-95.
11. Crippa G et al. Intrinsic possibilities of chest X-rays as a means to assess pulmonary congestion and water. J Am Coll Cardiol 1998; 31: 63C (abstract).
12. Sverzellati E et al. Functional purport of the cardiotho-racic ratio in congestive heart failure. J Cardiac Fail 1998; 4 (Suppl 1): 44 (abstract).
13. Acosta-Barrios T, Reyes AJ, Leary WP, van der Byl K. Effects of xipamide in hypertensive patients with cardiac insufficiency: a clinical appraisal. Curr Ther Res 1983; 33: 855-859.
14. Lipkin DP, Poole-Wilson P. Symptoms limiting exercise in chronic heart failure. BMJ 1992; 292: 1030-1031.
15. Lipkin DP, Canepa-Anson R, Stephens MR, Poole-Wilson PA. Factors determining symptoms in heart failure: comparison of fast and slow exercise tests. Br Heart J 1986; 55: 439-445.
16. Coats AJS. Origin of symptoms in heart failure. Cardiovasc Drugs Ther 1997; 11: 265-272.
17. Reyes AJ. Diuretics in heart failure. In: Puschett JB, Greenberg A (eds). Diuretics II: Chemistry, Pharmacology, and Clinical Applications. Elsevier Science: New York, 1987, pp 332-344.
18. Reyes AJ. Aspects of the mechanism of action of diuretics in heart failure. In: Andreucci VE, Dal Canton A (eds). Diuretics: Basic, Pharmacological, and Clinical Aspects. Martinus Nijhoff: Boston, 1987, pp 344-349.
19. Reyes AJ. Therapy with diuretics in congestive heart failure. Prog Pharmacol 1988; 6/3: 167-192.
20. Reyes AJ. Actions of diuretics on the functional processes of congestive heart failure: from facts to heuristic hypotheses. Prog Pharmacol Clin Pharmacol 1992; 9: 441-460.
21. Reyes AJ. Loop diuretics versus others in the treatment of congestive heart failure after myocardial infarction. Cardiovasc Drugs Ther 1993; 7: 869-876.
22. Zelis R, Sinoway L, Musch T, Davis D. The peripheral distribution of cardiac output in heart failure. Z Kar-diol 1988; 77 (Suppl 5): 61-65.
23. Matthay MA, Tibayan FA. Mechanisms for the formation and reabsorption of pulmonary edema. In: Cosen-tino AM, Martin RJ (eds). Cardiothoracic Interrelationships in Clinical Practice. Futura: Armonk, NY, 1997, pp 31-53.
24. Haddad PA, Bailey CA, Gray A. Respiratory considerations in congestive heart failure: pathophysiology, assessment and management. In: Cosentino AM, Martin RJ (eds). Cardiothoracic Interrelationships in Clinical Practice. Futura: Armonk, NY, 1997, pp 69-122.
25. Schaufelberger M et al. Skeletal muscle alterations in patients with chronic heart failure. Eur Heart J 1997; 18: 971-980.
26. Mancini DM, Henson D, LaManca J, Levine S. Respiratory muscle function and dyspnea in patients with chronic congestive heart failure. Circulation 1992; 86: 909-918.
27. Cowley AJ et al. Symptomatic assessment of patients with heart failure: double-blind comparison of increasing doses of diuretics and captopril in moderate heart failure. Lancet 1986; 2: 770-772.
28. Biddle TL, Yu PN. Effect of furosemide on hemodynamics and lung water in acute pulmonary edema secondary to myocardial infarction. Am J Cardiol 1979; 43: 86-90.
29. Sullivan MJ, Higginbotham MB, Cobb FR. Exercise training in patients with severe left ventricular dysfunction: hemodynamic and metabolic effects. Circulation 1988; 78: 506-515.
30. Minotti JR et al. Skeletal muscle response to exercise training in congestive heart failure. J Clin Invest 1990; 86: 751-758.
31. Adamapoulos S et al. Physical training improves skel-etal muscle metabolism in patients with chronic heart failure. J Am Coll Cardiol 1993; 21: 1101-1106.
32. Stratton JR et al. Training partially reverses skeletal muscle metabolic abnormalities during exercise in heart failure. J Clin Invest 1994; 76: 1572-1582.
33. Hambrecht R et al. Physical training in patients with stable chronic heart failure: effects on cardiorepiratory fitness and ultrastructural abnormalities of leg muscles. J Am Coll Cardiol 1995; 25: 1239-1249.
34. Coats AJS et al. Controlled trial of physical training in chronic heart failure: exercise performance, hemodynamics, ventilation, and autonomic function. Circulation 1992; 85: 2119-2131.
35. Mancini DM et al. Benefit of selective respiratory muscle training on exercise capacity in patients with chronic congestive heart failure. Circulation 1995; 91: 320-329.
36. Kiilavuory K et al. Effect of physical training on exercise capacity and gas exchange in patients with chronic heart failure. Chest 1999; 110: 985-991.
37. Reyes AJ, Taylor SH. Diuretics in cardiovascular medicine: the new clinicopharmacological bases that matter. Cardiovasc Drugs Ther 1999; 13: 371-398.
38. Velaázquez H. Thiazide diuretics. Renal Physiol 1987; 10: 184-197.
39. Greger R, Wangemann P. Loop diuretics. Renal Physiol 1987; 10: 174-183.
40. Horisberger J-D, Giebisch G. Potassium-sparing diuretics. Renal Physiol 1987; 10: 198-220.
41. Reyes AJ. Effects of diuretics on renal excretory function. Eur Heart J 1992; 13 (Suppl G): 15-21.
42. Reyes AJ, Leary WP. Clinicopharmacological definition of the potency of diuretics and reclassification of diuretics by their clinicopharmacological potency. Prog Pharmacol Clin Pharmacol 1992; 9: 131-146.
43. Leary WP, Reyes AJ, van der Byl K. The antialdosterone substance spironolactone is a facultative natriuretic, antikaliuretic and antimagnesiuretic in man. In: Puschett JB, Greenberg A (eds). Diuretics IV: Chemistry, Pharmacology and Clinical Applications. Excerpta Medica: Amsterdam, 1993, pp 391-394.
44. Pitt B et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-717.
45. Weber KT, Brilla CG, Campbell SE. Regulatory mechanisms of myocardial hypertrophy and fibrosis: results of in vivo studies. Cardiology 1992; 81: 266-273.
46. Brilla CG. Aldosterone and myocardial fibrosis in heart failure. Herz 2000; 25: 299-306.
47. Materson BJ. Diuretic therapy of hypertension in the United States: low-dose becomes lower. Prog Pharmacol Clin Pharmacol 1995; 10/3: 33-45.
48. Leary WP, Reyes AJ, van der Byl K. Interactions between different diuretics and between diuretics and other drugs on renal excretions in healthy man: mechanisms and clinical implications. Prog Pharmacol Clin Pharmacol 1992; 9: 317-360.
49. van der Byl K, Leary WP, Reyes AJ. Renal excretory actions of diuretics in congestive heart failure. Prog Pharmacol Clin Pharmacol 1992; 9: 371-380, 1992.
50. Cutillo AG. The clinical assessment of lung water. Chest 1987; 92: 319-325.
51. Brater DC. Diuretic resistance in chronic congestive heart failure: combinations of relatively low doses rather than very high doses. Prog Pharmacol Clin Pharmacol 1995; 10/3: 119-129.
52. Bayliss J et al. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J 1987; 57: 17-22.
53. Westheim AS et al. Hemodynamic and neuroendocrine effects for candoxatril and frusemide in mild stable chronic heart failure. J Am Coll Cardiol 1999; 34: 1794-1801.
54. Francis GS et al. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Ann Intern Med 1985; 103: 1-6.
55. Schrier RW, Martin PY. Recent advances in the understanding of water metabolism in heart failure. Adv Exp Med Biol 1998; 449: 415-426.
56. Spital A. Diuretic-induced hyponatremia. Am J Nephrol 1999; 19: 447-452.
57. Reyes AJ, Leary WP. Kaliuretic potency of thirty-one oral formulations of diuretics: report on a study series in progress. Am J Hypertens 2000; 13: 114A (abstract).
58. Cohn JN, Kowey PR, Whelton PK, Prisant LM. New guidelines for potassium replacement in clinical practice: a contemporary review by the National Council on Potassium in Clinical Practice. Arch Intern Med 2000; 160: 2429-2436.
59. Ponce SP, Jennings AE, Madias NE, Harrington JT. Drug-induced hyperkalemia. Medicine 1985; 64: 357-370.
60. Preston RA, Hirsh MJ, Oster JR, Oster HR. University of Miami Division of Clinical Pharmacology therapeutic rounds: drug-induced hyperkalemia. Am J Ther 1998; 5: 125-132.
61. Friedman PA, Bushinsky DA. Diuretic effects on calcium metabolism. Semin Nephrol 1999; 19: 551-556.
62. Yendt ER, Cohanim M. Prevention of calcium stones with thiazides. Kidney Int 1978; 13: 397-409.
63. Stier CT, Itskovitz HD. Renal calcium metabolism and diuretics. Annu Rev Pharmacol Toxicol 1986; 26: 101-116.
64. Reyes AJ, Leary WP, van der Byl K. Responses of urinary chloride, sodium, potassium and magnesium excretions to the addition of captopril to a combination of furosemide and amiloride. In: Puschett JB, Greenberg A (eds). Diuretics IV: Chemistry, Pharma-cology and Clinical Applications. Elsevier Science: Amsterdam, 1993, pp 595-598.
65. Costanzo L. Effects of diuretics on the distal convoluted tubular transport of calcium. In: Puschett JB, Greenberg A (eds). Diuretics: Chemistry, Pharmacology, and Clinical Applications. Elsevier: New York, 1984, pp 169-173.
66. Ghamdi SM, Cameron EC, Sutton RA. Magnesium deficiency: pathophysiologic and clinical overview. Am J Kidney Dis 1994; 24: 737-752.
67. Reyes AJ, Leary WP. Diuretics and magnesium. Magnes Bull 1984; 6: 87-99.
68. Reyes AJ, Leary WP. Magnesiuretic potency of twenty-seven oral formulations of diuretics. Report on a study series in progress. Am J Hypertens 2000; 4: 113A-114A (abstract).
69. Reyes AJ, Leary WP. Cardiovascular toxicity of diuretics related to magnesium depletion. Human Toxicol 1984; 3: 351-372.
70. Reyes AJ. Interactions between magnesium and drugs in congestive heart failure. Magnes Bull 1987; 9: 93-109.
71. Ceremuzynski L, Gebalska J, Wolk R, Makowska E. Hypomagnesemia in heart failure with ventricular arrhythmias. Beneficial effects of magnesium supplementation. J Intern Med 2000; 247: 78-86.
72. Vannini SD et al. Permanently reduced plasma ionized magnesium among renal transplant recipients on cyclosporine. Transpl Int 1999; 12: 244-249.
73. Dyckner T, Wester PO. Ventricular extrasystoles and intracellular electrolytes before and after potassium and magnesium infusions in patients on diuretic treatment. Am Heart J 1979; 97: 12-18.
74. Sowers JR. The impact of diuretics on potassium and glucose. J Cardiovasc Pharmacol 1989; 36: 111-117.
75. Furman BL. Impairment of glucose tolerance produced by diuretics and other drugs. Pharmacol Ther 1981; 12: 613-649.
76. Levine SN, Sanson TH. Treatment of hyperglycaemic hyperosmolar non-ketotic syndrome. Drugs 1989; 38: 462-472.
77. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality. The NHANES I epidemiologic follow-up study, 1971-1992. JAMA 2000; 283: 2404-2410.
78. Anker S et al. A simple predictor of impaired prognosis in chronic heart failure: uric acid. J Am Coll Cardiol 1998; 31: 197C (abstract).
79. Bettencourt P et al. Predictors of prognosis in patients with stable mild to moderate heart failure. J Card Fail 2000; 6: 306-313.
80. Johnson MW, Mitch WE. The risks of asymptomatic hyperuricaemia and the use of uricosuric diuretics. Drugs 1981; 21: 220-225.
81. Mazzali M et al. An elevated serum uric acid (UA) causes kidney damage: evidence for a crystal independent mechanism. Am J Hypertens 2000; 13: 36A (abstract).
82. Osaki S et al. Impairment of urate excretion is an important mechanism for hyperuricemia in patients with heart failure. J Card Fail 1999; 5 (Suppl 2): 60 (abstract).
83. Tykarski A. Evaluation of renal handling of uric acid in essential hypertension: hyperuricemia related to decreased urate secretion. Nephron 1991; 59: 364-368.
84. Reyes AJ. Renal excretory profiles of loop diuretics-consequences for therapeutic application. J Cardiovasc Pharmacol 1993; 22 (Suppl 3): S11-S23.
85. Carlsen JE, Kober L, Torp-Pedersen C, Johansen C. Relations between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. BrMed J 1990; 300: 975-978.
86. Frohlich ED. Ticrynafen: a new thiazide-like but uricosuric antihypertensive diuretic. N Engl J Med 1979; 301: 1378-1382.
87. Reyes AJ, Leary WP, van der Byl K. Lack of effect of cicletanine on uric acid. Am J Hypertens 2000; 13: 114A (abstract).
88. Tarrade T et al. Efficacite antihypertensive et tolerance du cicletanine. Resultats obtenues en monother-apie sur une large population. Arch Mal Coeur 1989;82: 91-97.
89. Leary WP, Reyes AJ. Angiotensin I converting enzyme inhibitors and the renal excretion of urate. Cardiovasc Drugs Ther 1987; 1: 29-38.
90. Reyes AJ. Angiotensin-converting enzyme inhibitors in the clinical setting of congestive heart failure. Am J Cardiol 1995; 75: 50F-55F.
91. Lant AF, McNabb RW, Noormohamed FH. Kinetic and metabolic aspects of enalapril action. J Hypertens 1984; 2 (Suppl 2): 37-42.
92. Leary WP, Reyes AJ, van der Byl K, Acosta-Barrios TN. Effects of captopril, hydrochlorothiazide and their combination on timed urinary excretion of water and electrolytes. J Cardiovasc Pharmacol 1985;7;(Suppl 1): S56-S62.
93. Labeeuw M et al. Influence de l'administration aigue du ramipril sur l'excretion d'acide urique. Arch Mal Coeur 1987; 80: 870-874.
94. Reyes AJ, Uric acid in cardiovascular diseases and the uricosuric and hypouricaemic actions of angiotensin-converting enzyme inhibitors. In: Reyes AJ, Maranhao MFC (eds). Cardiovascular pharmacotherapy. Proceedings of the 9th International Congress on Cardiovascular Pharmacotherapy. Monduzzi: Bologna, 2000, pp 235-240.
95. Nakashima M, Uematsu T, Kosuge K, Kanamuro M. Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 1992; 42: 333-335.
96. Soffer BA et al. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension 1995; 26: 112-117.
97. Kochar M et al. Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. Am JHypertens 1999; 12: 797-805.
98. Greenberg A. Diuretic complications. Am J Med Sci 2000; 319: 10-24.
99. Puschett JB, Lupinacci Jordan L. Mode of action of torasemide in man. Prog Pharmacol Clin Pharmacol 1990; 8/1: 3-13.
100. Reyes AJ, Leary WP, Espinas RD, van der Byl K. The loop diuretic torasemide does not act on the proximal tubule of the nephron. Eur Heart J 2000; 21 (Abstract Suppl): 440 (abstract).